Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Inclusion Criteria

• Patients >= 18 years old at the time of informed consent
• Ability to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
• Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on American Joint Committee on Cancer (AJCC) staging
• Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
• Able to undergo general anesthesia for sentinel lymph node biopsy
• Able to undergo CT scan with contrast or magnetic resonance imaging (MRI) with contrast
• Undergo surgical resection (Moh’s or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging

Exclusion Criteria

• Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases
• Known biopsy proven synchronous primary cutaneous squamous cell carcinoma of the head and neck * Note: Secondary cutaneous malignancies are allowed
• Pregnant patients
• Patients unable to undergo general anesthesia
• Patient unable to receive contrasted imaging studies
• Patient unable to receive and/or allergic to 99m-technetium sulfur colloid